Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-08
2005-03-08
Tate, Christopher (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S102000, C514S108000
Reexamination Certificate
active
06864228
ABSTRACT:
This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average IDS). Then the administration of the bisphosphonate preparation is interruption in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bisphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again. The proposed procedure of a period with bisphosphonate followed by another period without the bisphosphonate agent improves fracture resistance, provided that the length of both periods is controlled by defined osteologic variables.
REFERENCES:
patent: 5403829 (1995-04-01), Lehtinen
patent: 5409911 (1995-04-01), Tyler
Glorieux, 1998, “Cyclic administration of pamidronate in children with severe osteogenesis imperfecta” New England journal of Medicine, 339 (14): pp 947-952.*
Landsmeer-Beker, 1997 “Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate” Eur. J. Pediatr., 156 (10): pp. 792-794.*
Bembi, 1997 “Intravenous pamidronate treatment in osteogenesis imperfecta” J. Pediatr. 131 (4): 622-625.*
Plotkin, 2000, “Medical treatment of osteogenesis imperfecta” Drug Dev. Res. 49 (3):141-145.
Perez Lloret Anibal
Roldan Emilio J. A.
Gador S.A.
Pendorf & Cutliff
Tate Christopher
Teller Roy
LandOfFree
Use of bisphosphonates for the treatment of osteogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of bisphosphonates for the treatment of osteogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bisphosphonates for the treatment of osteogenesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456350